Smruthi Organics Ltd. engages in the manufacture and sale of bulk drugs and drug intermediates. The company is headquartered in Solapur, Maharashtra and currently employs 308 full-time employees. The company went IPO on 2017-08-29. The Company’s segments include Bulk Drugs and Drugs Intermediates and Formulation. The company manufactures API products in the anti-diabetic, anti-hypertension and anti-infectives therapeutic categories. Its products include Amlodipine Besilate, Losartan Potassium, Telmisartan, Metformin HCL, S-Amlodipine Besilate, S-Amlodipine Malelate, Valsartan, Vildagliptin, Teneligliptin, Ciprofloxacin HCL, Diloxanide Furoate, Norfloxacin, Pefloxacin Mesylate, Ticagrelor, and others. The company caters to both the Indian domestic as well as the rest of the world (ROW) markets, with clients spanning Asia, the Americas, and Africa. The firm has two manufacturing facilities in Solapur, India. The API facility is spread across 22-acre land.

Smruthi Dividends

540686.BO dividend metrics

Dividend per share

540686.BO dividend history